B. Ellsworth

发表

Chapter Twenty-Eight – To Market, To Market—2012

J. Bronson, Amelia Black, T. G. Dhar, 2013 .

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Steven A. Spronk, K. Behnia, J. Barrish, 2022, Journal of medicinal chemistry.

Modulateurs dihydropyrazoles de gpr40

Z. Gu, W. R. Ewing, Ximao Wu, 2013 .

Synthesis and evaluation of inhibitors of bacterial D-alanine:D-alanine ligases.

P. Bartlett, N. J. Tom, B. Ellsworth, 1996, Chemistry & biology.

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

W. Humphreys, B. Koplowitz, A. Khanna, 2010, Drug Metabolism and Disposition.

Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 ( SGLT 2 ) Dapagliflozin for the Treatment of Type 2 Diabetes

B. Ellsworth, W. Washburn, P. Deshpande, 2022 .

Structural and Thermal Characterization of Halogenated Azidopyridines: Under-Reported Synthons for Medicinal Chemistry.

Darpandeep Aulakh, Amy A Sarjeant, P. Cheng, 2021, Organic letters.

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

W. Humphreys, T. Waldron, Songping Han, 2008, Bioorganic & medicinal chemistry letters.

A Practical Stereoselective Synthesis and Novel Cocrystallizations of an Amphiphatic SGLT-2 Inhibitor

S. Leung, R. Randazzo, K. Volk, 2012 .

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.

David S. Nirschl, Kimberly A. Foster, David S Nirschl, 2017, Journal of medicinal chemistry.

Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.

J. Krupinski, A. Azzará, Gary G Cao, 2021, ACS medicinal chemistry letters.

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.

C. Chu, S. Jusuf, Yanou Yang, 2021, Journal of medicinal chemistry.

C-Arylglucoside synthesis: triisopropylsilane as a selective reagent for the reduction of an anomeric C-phenyl ketal

A. Doyle, W. Meng, B. Ellsworth, 2003 .

Preparation of N-alkyl 2-pyridones via a lithium iodide promoted O- to N-alkyl migration: scope and mechanism.

Keun Ah Ryu, B. Ellsworth, Erica L. Lanni, 2012, The Journal of organic chemistry.

Synthesis of substituted N-benzyl pyridones via an O- to N-alkyl migration.

B. Ellsworth, Erica L. Lanni, Carolyn E Anderson, 2008, The Journal of organic chemistry.

Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3.

B. Beno, A. Mathur, Chunjian Liu, 2022, Journal of medicinal chemistry.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

W. Humphreys, O. Flint, E. Janovitz, 2008, Journal of medicinal chemistry.

Segment-coupling Prins cyclizations

S. Rychnovsky, Yueqing Hu, B. Ellsworth, 1998 .

Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Dapagliflozin for the Treatment of Type 2 Diabetes

B. Ellsworth, W. Washburn, P. Deshpande, 2014 .

Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Ying Wang, Samuel W Gerritz, William R Ewing, 2007, Bioorganic & medicinal chemistry letters.

Chapter Twenty-Seven – To Market, To Market—2013

M. Dhar, J. Bronson, Amelia Black, 2014 .

Remarkable beta-selectivity in the synthesis of beta-1-C-arylglucosides: stereoselective reduction of acetyl-protected methyl 1-C-arylglucosides without acetoxy-group participation.

F. Buono, B. Ellsworth, Janak Singh, 2007, The Journal of organic chemistry.

Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors.

B. Beno, Amit Kumar, K. Ghosh, 2021, Journal of medicinal chemistry.

Amination of Nitro-Substituted Heteroarenes by Nucleophilic Substitution of Hydrogen.

Darpandeep Aulakh, M. Davies, B. Ellsworth, 2022, Organic letters.

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.

S. E. Kiefer, J. Krupinski, Srinivas Cheruku, 2022, Journal of medicinal chemistry.

Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.

K. Behnia, N. Murugesan, Z. Gu, 2013, Journal of medicinal chemistry.

Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.

Kimberly A. Foster, Michael A. Galella, J. Barrish, 2023, Bioorganic & medicinal chemistry.

Synthesis of Bicyclo[1.1.0]butanes from Iodo-Bicyclo[1.1.1]pentanes.

Maximilian D Palkowitz, Darpandeep Aulakh, B. Ellsworth, 2023, Organic Letters.

Discovery and exploration of monosaccharide linked dimers of galectin-3 inhibitors to target fibrosis

B. Beno, J. Yanchunas, Chunjian Liu, 2023, Medicinal Chemistry Research.

Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383.

W. R. Ewing, M. Pelleymounter, Qi Huang, 2011, European journal of pharmacology.